⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004) (P4-14.017)

Vera Bril Artur Drużdż Julian Großkreutz Ali A. Habib Henry J. Kaminski Renato Mantegazza Sabrina Sacconi Kimiaki Utsugisawa Tuan Vu Marion Boehnlein Franz Woltering Bernhard Greve Maryam Gayfieva John Vissing

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the safety, tolerability and efficacy of chronic, weekly rozanolixizumab in patients with generalized myasthenia gravis (MG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bril et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcb5b6db643587676eb5 https://doi.org/10.1212/wnl.0000000000205615

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis (P10-11.005)2024
2Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia GravisOriginal Research · 2026
3Treatment Characteristics and Healthcare Resource Utilization Among Patients With Generalized Myasthenia Gravis Initiating Rozanolixizumab in the United States (P4-9.007)Original Research · 2026
4Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database AnalysisLate-Phase Clinical Trial · 2026
5Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study2025